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| INTRODUCTION
To establish effective therapy for disease, numerous techniques have been developed to study the function of genes and proteins known to be involved. Conditional knockout mouse models have been successfully generated and applied in many areas of research (Hall, Limaye, & Kulkarni, 2009) . However, the function of target proteins often cannot be analyzed in these models because of embryonic lethality resulting from a fatal gene deficiency. Conditional genetically engineered mouse models were later developed; in particular, Cre-lox technology is a useful approach to inactivate genes in mice (Danielian, Muccino, Rowitch, Michael, & McMahon, 1998; Taniguchi et al., 2011) , and however, this approach is not reversible, and the identification of a suitable promoter can be difficult. The tetracycline-controlled tet-off and tet-on gene expression systems are widely used to reversibly and quantitatively target various genes at the transcriptional level (Ryding, Sharp, & Mullins, 2001) , and RNA interference is rapidly being adopted as a method to achieve post-transcriptional gene silencing (Fire et al., 1998; Medema, 2004) . However, these methods have drawbacks, including large side effects such as the binding of tamoxifen to native estrogen receptors (Roshangar, Rad, & Afsordeh, 2010) , the inability of high molecular weight ligands to cross the blood-brain barrier, and the relatively slow kinetics of induction and repression (Liu et al., 2012) . Furthermore, all of these experimental approaches have limitations in regulating proteins directly, especially in mammalian cells.
Recently, Wandless and coworkers developed a general method for direct pharmacological control of protein stability (Banaszynski, Chen, Maynard-Smith, Ooi, & Wandless, 2006; Iwamoto, Bjorklund, Lundberg, Kirik, & Wandless, 2010) . This technology utilizes mutant destabilizing domain (DD) from bacterial dihydrofolate reductase (ecDHFR), which can be attached to virtually any protein of interest (POI). Newly synthesized DD-POIs containing ecDHFR tags are degraded through the proteasome pathway, but their degradation can be blocked with the ligand trimethoprim (TMP). TMP is a type of antibiotic that acts as a DHFR inhibitor and interferes with folate metabolism in bacteria. TMP can be easily applied to experimental animals, showing a high rate of diffusion in peripheral tissues and nervous system, and does not have endogenous targets in mammals (Iwamoto et al., 2010; Tu, Allen, Fiorica, & Albers, 1989) . Moreover, TMP can cross the blood-brain barrier (Barling & Selkon, 1978) and also passes the placental barrier (Schulz, 1972) , so it can be delivered to the embryo. Wandless and colleagues have verified the function of the DD system in vitro and lentivirus injection animals in vivo (Banaszynski et al., 2006; Iwamoto et al., 2010) .
To enhance the above technology, we have generated a novel conditional transgenic mouse model named the YB1-DD mouse, in which the YB1 gene is fused with the DD to enable direct control of protein expression. YB-1 is a transcriptional and translational factor that regulates many cellular processes such as cell proliferation, DNA repair, cellular stress response, cell differentiation, embryonic development, and inflammation (Eliseeva, Kim, Guryanov, Ovchinnikov, & Lyabin, 2011; Kohno, Izumi, Uchiumi, Ashizuka, & Kuwano, 2003; Wang et al., 2017) . YB-1 belongs to a large family of proteins that contain a conserved nucleic acid-binding domain termed the cold shock domain (CSD). YB-1 is widely expressed throughout development and has been implicated as a cell survival factor. Analysis of YB1 knockout animals revealed that YB-1 deficiency resulted in multi-organ hypoplasia and embryonic/perinatal lethality, indicating that YB-1 is essential for the normal development of multiple mammalian embryonic organ systems and for perinatal survival (Lu, Books, & Ley, 2005; Uchiumi et al., 2006) .
In this study, we created a new conditional transgenic mouse model in which the YB1 gene was fused with the DD. Newly synthesized YB-1-DD protein is degraded through the proteasome pathway, but the target protein YB-1 can be stabilized by the ligand TMP in this mouse model. We attempted to control target protein degradation directly in this model by TMP administration.
| RESULTS

| Generation of YB1-DD
+/− mice
A targeting vector was constructed by replacing the genomic locus containing the seventh exon of the YB1 gene, which encodes the destabilized domain (DD, mutant of Escherichia coli), with a neomycin-resistance gene (Neor) under the control of a PGK1 promoter for positive selection (Figure 1 ). The targeting vector was electroporated into ES cells, and the chimeric mice were generated by an aggregation method. To generate heterozygous offspring, male chimeric mice were mated with C57BL/6J female mice, and YB1 +/− C57BL/6J F1 progeny were obtained. In this study, we used mice with the C57BL/6J background. Mice were backcrossed with Table S1 .
| Evaluation of YB1 expression in wildtype and YB1-DD +/− mice in various organs
The be detected in postnatally developing mice in these organs reported by previous study (Miwa, Higuchi, & Kobayashi, 2006) . Expression of YB-1 was significantly lower in YB1-DD +/− mouse pups. These results suggested that heterozygous mice were successfully developed.
| Upregulation of YB-1 expression by TMP in YB1-DD +/− mice
Then we investigated if stabilization of YB-1 protein was dependent on TMP dose in our mouse model. The YB1-DD +/− mice were intraperitoneally administered TMP at a dose range of 50-150 mg/kg. The control mice were given 10% DMSO in saline. One day after injection, the mice were killed and levels of YB-1 protein were examined in the kidney, spleen and liver. YB-1 expression was increased in a dose-dependent manner and was significantly enhanced in the kidney (Figure 3a ,b) and the spleen (Figure 3c,d) . However, the change was less evident in the liver ( Figure  3e ,f). Similar variations were observed regardless of sex as shown in the spleen and liver (Figure 3c-f) . Moreover, immunohistochemistry results also showed increased expression of YB-1 in the kidney and spleen (Figure 3g ,h). YB1 exhibits differential increases in expression among the examined organs. It has been reported that TMP distribution was higher in the kidney and spleen than the liver after intravenous administration in rat (Schulz, 1972; Tu et al., 1989) . Therefore, the regulation of YB-1 by TMP may be more sensitive in the kidney and spleen than the liver ( Figure  3a -f), consistent with previous studies. Furthermore, we investigated YB-1 regulation in the brain, skeletal muscle and heart in 2-week-old mice following administration of TMP 
| DISCUSSION
We have successfully created a new conditional transgenic mouse model, YB1-DD
, in which the expression levels of target protein YB-1 could be controlled by the concentration of TMP ligand. We found that YB-1 could be regulated in various organs in a dose-dependent manner in the heterozygous mice. To our knowledge, this is the first mouse model in which the target protein could be regulated directly. Instead of regulating transgenes at the transcriptional level, this new model directly regulates proteins at the degradation level. This in vivo regulation is achieved by fusing the transgene product with a destabilizing domain, which makes the fusion protein unstable and prone to proteasome degradation; degradation can be avoided by treatment with TMP ligand.
YB-1 is important in modulating inflammatory pathways including both pro-and anti-inflammatory pathways, as well as repair (Hanssen et al., 2013; Wang et al., 2017) . Transient upregulation of YB-1 occurs in kidney and in heart recovering from ischemia-reperfusion (I/R) injury during the acute phase of inflammation in experimental inflammation models. However, these previous studies stated that a YB1-DD +/− mouse model had to be used because homozygous YB1-deficient mice are not viable, and the level of YB1 expression in their heterozygous mice could not be regulated, only exhibiting half the levels of that in wild-type mice. We created a novel YB1-DD +/− mice model in which YB-1 protein could be regulated with a ligand in a dose-dependent manner. Thus, our model seems to be very useful for studying the mechanism of inflammation and repair processes, and for developing optimal therapies for damage in these organs. As mentioned above, YB1 knockout mice are not viable because of embryonic lethality. Previous studies revealed that TMP could be delivered to the embryo by passing across the placental barrier (Schulz, 1972) and can also cross the bloodbrain barrier (Barling & Selkon, 1978; Iwamoto et al., 2010; Tai, Quintino, Isaksson, Gussing & Lundberg, 2012) . In our study, YB-1 was significantly enhanced in the brain, skeletal muscle and heart of 2-week-old mice pups following administration of TMP to their mother, indicating TMP could be delivered to the brain of mice pups. Therefore, we attempted to generate YB1-DD −/− mice by administering TMP (0.1 mg/ml) daily in drinking water following mating with heterozygous DD mice. One homozygous YB1-DD mouse was generated (Supporting Information Figure S2a,b) , and however, the homozygous mouse died on day 1. Although the homozygous mouse died after birth, severe cerebral hernia and bleeding was not observed as previously reported (Lu et al., 2005; Uchiumi et al., 2006) . This suggests that the abnormality in the brain of the YB1-DD homozygous mouse was partly rescued by administration of TMP to the mother, which subsequently crossed the placenta; however, the dose may be insufficient, resulting in the death of the newborn. We need to develop effective methods for TMP administration to mice, and to rescue the YB1-DD homozygous mouse model in the future. Furthermore, we attempted to examine YB-1 regulation of downstream molecules such as MDR1; however, MDR1 showed only slightly increased expression following YB-1 upregulation by TMP in the brains of YB1-DD +/− mice. In previous studies, changes in some molecules downstream of YB-1 were observed only in YB1 −/− mouse embryonic fibroblast (MEFs), but not in YB1-DD +/− MEFs (Lu et al., 2005; Uchiumi et al., 2006) . Moreover, immune-related factors differed only in the renal inflammation models of wild-type and heterozygous mice, and no difference was observed in normal heterozygous mice. Therefore, downstream regulation may be not observed in normal heterozygous mice as it could only be achieved in some disease models using YB1 heterozygous mice. We are now considering investigations of these observations in a future paper. Although there are some limitations to this model, we successfully generated YB1-DD knockin mice using the DD system, in which the targeting protein can be regulated by the TMP ligand. TMP can be easily used in experimental animals and can be delivered to embryos and newborns through their mother, with fast dispersal to all tissues after intravenous administration (Tu et al., 1989) , and high concentrations presented no adverse effects in the rat (Iwamoto et al., 2010) . Another critical advantage of the DD system is that TMP can be orally administered with good pharmacological characteristics, which is a less invasive and more convenient method than injection. Taking into consideration of the abovementioned factors, our mouse model should be particularly attractive and offers advantages including the avoidance of embryonic lethality, resolving drug resistance in cancer and autoimmune disease, clarifying the mechanism of inflammation, and predicting applicable therapies.
| EXPERIMENTAL PROCEDURES
| Mice
C57BL/6J mice and FLPe mice were purchased from CLEA Japan, Inc. (Tokyo, Japan) and Riken BRC in Japan (Tsukuba, Japan). YB1-DD +/− mice were generated and maintained on a C57BL/6J background. All of the animal experiments were approved by the Committee on Animal Experimentation of the Tokyo University of Science.
| Administration of regents
For the dosing study, adult YB1-DD +/− mice were treated with TMP (50, 100, and 150 mg/kg of body weight) by intraperitoneal injection. To investigate regulation in the brain, skeletal muscle and heart, which can only be detected in postnatally developing mice, 0.2 mg/ml TMP was administered daily via drinking water for 10 days from 1 week after birth, and the mother was given a single intraperitoneal injection (150 mg/kg of body weight) one day before sampling. For the homozygous DD mouse generation experiment, 0.1 mg/ ml TMP was administered daily in drinking water following mating with the YB1-DD +/− mice. Reagent solutions for injection were reconstituted in 10% DMSO (Nacalai Tesque, Kyoto, Japan) and diluted in normal saline (Nacalai Tesque), and the solutions were prepared fresh for every experiment. Intraperitoneal injections were carried out using a 27-g needle. Vehicle solution containing 10% DMSO in normal saline was used as a control.
| Protein preparation from tissue
Tissue from animals was homogenized in TKM buffer as previously described (Miwa et al., 2006) : 50 mM triethanolamine (pH 7.8), 50 mM KCl, 5 mM MgCl 2 , 0.25 M sucrose, 1 mM PMSF, protein inhibitors (Nacalai Tesque), 1 mM DTT and ribonuclease inhibitor (0.2 unit/ μl, TAKARA Bio., Shiga, Japan). Tissue lysates were centrifuged at 1,000 g for 15 min to 30 min to obtain the supernatant.
| Western blot analysis
Tissues lysates were resolved by SDS-PAGE and then transferred onto PDVF membranes (Merck Millipore Ltd., Darmstadt, Germany). The membranes were blocked with 5% nonfat milk in TBS-T (containing 1%-2% Tween 20). Rabbit monoclonal antibody against YB-1 [EP2708Y] (1:10,000, ab76149; Abcam Inc., Cambridge, UK), mouse monoclonal antibody against β-actin (AC-15) (1:10,000, sc-69879; Santa Cruz Biotechnology, Inc., Texas, USA) and GAPDH (6C5) (1:20,000, sc-32233; Santa Cruz Biotechnology, Inc., Texas, USA) were used with anti-mouse IgG-HRP (1:20,000, A90-116P; Bethyl Laboratories, Inc., Montgomery, USA) and anti-rabbit IgG-HRP (1:10,000, ab6721; Abcam Inc.) secondary antibodies. Bands were detected by chemiluminescence (LAS-3000, Fujifilm, Tokyo, Japan).
